AAM Sees Mixed Progress On US Legislation

 
• By Dave Wallace

The latest health subcommittee amendments to generics- and biosimilars-related US draft legislation have provided a mixed bag for the AAM.

StepsSigns
The AAM Says The Latest Developments Represent “One Step Forward And Two Steps Back” • Source: Shutterstock

More from Policy & Regulation

More from Generics Bulletin